Publications: 112 in 2026-04. -7.4% share of all MeSH-indexed PubMed records vs the same month last year (124 in 2025-04).
PublicationsPubMed
1122026-04
-7.4% share of all MeSH-indexed PubMed records vs same month last year (124 in 2025-04)provisional · settling
0.10% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 16 in 2026-09. +14.3% vs the same month last year (14 in 2025-09).
Clinical trialsClinicalTrials.gov
162026-09
+14.3% vs same month last year (14 in 2025-09)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 58 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 58 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
582026-09
78th percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 323 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 323 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
3232026-09
91st percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 33 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 33 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
332026-09
78th percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 112 is in the 50th percentile, in its typical range, versus 320 months since 2000.
50thpercentile
in its typical range
112/mo · higher than 50% of 320 months since 2000
Clinical trials
Clinical trials: latest count 16 is in the 99th percentile, near its historical high, versus 320 months since 2000.
99thpercentile
near its historical high
16/mo · higher than 98% of 320 months since 2000
NIH grantsprovisional
NIH grants: latest count 58 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
78thpercentile
running high
58/mo · higher than 75% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 323 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
91stpercentile
near its historical high
323/mo · higher than 88% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 33 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
78thpercentile
running high
33/mo · higher than 75% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 320 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 299/mo
Clinical trials2000 to 2026 · 320 mopeak 17/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 94/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 359/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 42/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-08..2026-07
4%of works have an industry affiliation
German Center for Neurodegenerative Diseases162
University College London154
Inserm149
Massachusetts General Hospital129
University of Sheffield102
Clinical trials
Lead sponsors · 2023-10..2026-09
6%industry-led in 2026-09
Novartis PharmaceuticalsIndustry9
n-Lorem FoundationAcademic/other7
BiogenIndustry6
Istituto Auxologico ItalianoAcademic/other6
Neuralink CorpIndustry6
NIH grants
Funded institutions · 2025-06..2026-09
666awards in window
JOHNS HOPKINS UNIVERSITYMD · $19.2M · R01/F3132
COLUMBIA UNIVERSITY HEALTH SCIENCESNY · $19.5M · R01/F3131
WASHINGTON UNIVERSITYMO · $11.2M · R01/F3122
MASSACHUSETTS GENERAL HOSPITALMA · $72.8M · U01/R0119
UNIVERSITY OF MIAMI SCHOOL OF MEDICINEFL · $25.6M · U54/R0118
Patents
Applicants · 2025-06..2026-09
The Regents of the University of California76
Ionis Pharmaceuticals, Inc.45
Alnylam Pharmaceuticals, Inc.42
University of Massachusetts37
Hoffmann-La Roche Inc.28
Preprints
Corresponding institutions · 2025-06..2026-09
King's College London11
University of Pennsylvania7
McGill University6
Stanford University6
Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310000, China; Regenerative Bio Inc., Hangzhou, Zhejiang, China5
2026-09-28biorxivProgram in Molecular Biology and Microbiology, Graduate School of Biomedical Sciences, Tufts University, 150 Harrison Avenue, Boston, MA 02111, United States of
Would you read a monthly digest for Amyotrophic Lateral Sclerosis (ALS)?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Amyotrophic Lateral Sclerosis (ALS). Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Amyotrophic Lateral Sclerosis (ALS).
How we map "Amyotrophic Lateral Sclerosis (ALS)"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Amyotrophic Lateral Sclerosis"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10